비교리스트

 카트 문의
시장보고서
상품코드
1543899

세계의 항염증 치료제 시장

Anti-Inflammatory Therapeutics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 194 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항염증 치료제 시장은 2030년까지 1,522억 달러에 달할 전망

2023년에 1,131억 달러로 추정된 세계의 항염증 치료제 시장은 분석 기간인 2023-2030년에 CAGR 4.3%로 성장하며, 2030년에는 1,522억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 항염증 생물제제는 CAGR 4.4%를 기록하며, 분석 기간 종료시에는 677억 달러에 달할 것으로 예측됩니다. 비스테로이드성 항염증약(NSAIDs) 분야의 성장률은 분석 기간 중 CAGR 4.6%로 추정됩니다.

미국 시장은 299억 달러, 중국은 CAGR 6.6%로 성장 예측

미국의 항염증 치료제 시장은 2023년에 299억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 326억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년 CAGR은 6.6%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.7%와 3.4%로 예측됩니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계의 항염증 치료제 시장 - 주요 동향과 촉진요인 정리

현대 헬스케어에서 항염증 치료제의 중요성

항염증 치료제는 많은 만성·급성 질환의 중요한 요인인 염증을 관리하고 완화하는 데 매우 중요한 역할을 하므로 현대 의료에 필수적입니다. 자연 방어 메커니즘인 염증은 만성화되면 문제가 되어 류마티스 관절염, 염증성 장 질환, 심혈관 질환과 같은 질병의 원인이 될 수 있습니다. 비스테로이드성 항염증 치료제(NSAIDs), 코르티코스테로이드, 생물학적 제제를 포함한 항염증 치료제는 염증과 통증을 줄이고 환자의 삶의 질을 크게 향상시키는 데 필수적입니다. 이러한 약물은 다양한 의료 분야에서 광범위하게 사용되고 있으며, 급성기 치료와 장기적인 질병 관리 모두에서 그 중요성이 강조되고 있습니다.

항염증 치료제 개발을 촉진하는 기술 혁신이란?

기술 혁신은 항염증 치료제 개발에 혁명을 일으켜 보다 정확하고 효과적인 치료로 이어지고 있습니다. 생명공학 및 분자생물학의 획기적인 발전은 염증 경로를 구체적으로 표적으로 삼는 생물학적 치료의 길을 열었습니다. 단일 클론 항체 및 사이토카인 억제제와 같은 생물학적 제제는 면역 체계를 선택적으로 조절하여 표적 치료를 제공함으로써 기존 약물에 비해 큰 이점을 제공합니다. 유전체학 및 단백질체학의 발전으로 새로운 치료 타깃이 확인되고 있으며, 차세대 항염증 치료제 개발이 용이해지고 있습니다. 또한 서방형 제제 및 표적 전달 시스템과 같은 약물전달 기술의 발전은 이러한 치료제의 효능과 안전성을 강화하여 부작용을 최소화하고 환자의 순응도를 향상시키고 있습니다.

왜 항염증 치료제에 대한 수요가 건강 상태 전반에 걸쳐 증가하는 것일까?

항염증 치료제에 대한 수요가 급증하는 이유는 만성 염증성 질환의 유병률이 증가하고 염증이 많은 건강 상태에 관여한다는 인식이 확산되고 있기 때문입니다. 관절염, 천식, 염증성 장 질환과 같은 만성질환은 전 세계에서 수백만 명에게 영향을 미치고 있으며, 효과적인 항염증 치료에 대한 수요가 크게 증가하고 있습니다. 또한 고령화 사회는 만성 염증성 질환에 걸리기 쉽기 때문에 이러한 치료제에 대한 수요가 증가하고 있습니다. 수술, 부상, 감염으로 인한 급성 염증 반응 또한 효과적인 관리가 필요하며, 항염증 치료제의 적용 범위가 넓어지고 있습니다. 또한 염증과 암, 신경 퇴행성 질환 등의 질병과의 연관성에 대한 연구가 확대됨에 따라 새로운 치료제의 개발이 촉진되고, 그 적용 범위와 시장 잠재력이 확대되고 있습니다.

항염증 치료제 시장의 성장을 가속하는 요인은 무엇인가?

항염증 치료제 시장의 성장은 기술 발전, 염증성 질환의 유병률 증가, 치료 패러다임의 진화 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 생명공학 및 맞춤형 의료 분야의 혁신은 보다 정밀하고 효과적인 생물학적 제제의 개발로 이어졌으며, 이는 높은 정확도와 부작용 감소로 인해 점점 더 선호되고 있습니다. 특히 고령화 사회에서 관절염, 염증성 장 질환 등 만성 염증성 질환의 유병률 증가는 중요한 촉진요인입니다. 또한 의료비 지출 증가와 의료 서비스 접근성 향상으로 인해 염증성 질환을 치료할 수 있는 환자가 증가하고 있습니다. 다양한 질환에서 염증의 역할에 대한 인식이 높아지면서 미충족 의료 수요를 충족시킬 수 있는 혁신적인 치료제를 개발하기 위한 연구개발이 가속화되고 있습니다. 또한 제약업계의 전략적 제휴와 파트너십은 새로운 항염증 치료제의 개발 및 상용화를 가속화하여 시장 활성화와 확대에 기여하고 있습니다.

조사 대상 기업의 예(주목 42사)

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.09.03

Global Anti-Inflammatory Therapeutics Market to Reach US$152.2 Billion by 2030

The global market for Anti-Inflammatory Therapeutics estimated at US$113.1 Billion in the year 2023, is expected to reach US$152.2 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$67.7 Billion by the end of the analysis period. Growth in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$29.9 Billion While China is Forecast to Grow at 6.6% CAGR

The Anti-Inflammatory Therapeutics market in the U.S. is estimated at US$29.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$32.6 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Anti-Inflammatory Therapeutics Market - Key Trends and Drivers Summarized

How Essential Are Anti-Inflammatory Therapeutics in Modern Healthcare?

Anti-inflammatory therapeutics are integral to modern healthcare due to their pivotal role in managing and alleviating inflammation, a key factor in numerous chronic and acute conditions. Inflammation, a natural defense mechanism, becomes problematic when chronic, contributing to diseases such as rheumatoid arthritis, inflammatory bowel disease, and cardiovascular disorders. Anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics, are essential for reducing inflammation and pain, thereby significantly enhancing patient quality of life. These medications are widely used across various medical fields, highlighting their critical importance in both acute care and long-term disease management.

What Technological Innovations Are Advancing Anti-Inflammatory Drug Development?

Technological innovations are revolutionizing the development of anti-inflammatory drugs, leading to more precise and effective treatments. Breakthroughs in biotechnology and molecular biology have paved the way for biologic therapies that specifically target inflammatory pathways. Biologics, such as monoclonal antibodies and cytokine inhibitors, offer targeted treatment by selectively modulating the immune system, providing a significant advantage over traditional drugs. Advances in genomics and proteomics are identifying new therapeutic targets, facilitating the creation of next-generation anti-inflammatory agents. Additionally, improvements in drug delivery technologies, including sustained-release formulations and targeted delivery systems, are enhancing the efficacy and safety of these therapies, minimizing side effects and boosting patient adherence.

Why Is Demand for Anti-Inflammatory Therapeutics Increasing Across Health Conditions?

The demand for anti-inflammatory therapeutics is surging due to the rising incidence of chronic inflammatory diseases and the growing recognition of inflammation's role in numerous health conditions. Chronic conditions like arthritis, asthma, and inflammatory bowel disease impact millions globally, driving a substantial need for effective anti-inflammatory treatments. Furthermore, the aging population is more prone to chronic inflammatory ailments, increasing the demand for these therapeutics. Acute inflammatory responses, resulting from surgeries, injuries, and infections, also necessitate effective management, underscoring the wide-ranging applicability of anti-inflammatory drugs. Additionally, expanding research into the connection between inflammation and diseases such as cancer and neurodegenerative disorders is fostering the development of novel therapies, broadening their application and market potential.

What Factors Are Propelling Growth in the Anti-Inflammatory Therapeutics Market?

The growth in the anti-inflammatory therapeutics market is driven by several key factors, including technological advancements, the rising prevalence of inflammatory diseases, and evolving treatment paradigms. Innovations in biotechnology and personalized medicine are leading to the creation of more targeted and effective biologic therapies, which are increasingly preferred for their precision and reduced side effects. The growing incidence of chronic inflammatory conditions, such as arthritis and inflammatory bowel disease, is a significant driver, particularly among the aging population. Additionally, increasing healthcare expenditure and improved access to medical services are enabling more patients to receive treatment for inflammatory conditions. Enhanced awareness of inflammation's role in various diseases is fueling research and development, resulting in innovative therapies that address unmet medical needs. Furthermore, strategic collaborations and partnerships within the pharmaceutical industry are accelerating the development and commercialization of new anti-inflammatory drugs, contributing to a vibrant and expanding market landscape.

Select Competitors (Total 42 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Anti-Inflammatory Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Chronic Inflammatory Diseases Throws the Spotlight on Anti-Inflammatory Therapeutics
    • Advances in Biotechnology and Personalized Medicine Propel Growth in Therapeutic Options
    • Development of Biologic Therapies Expands Addressable Market Opportunity
    • Increasing Prevalence of Autoimmune Disorders Strengthens Business Case for Anti-Inflammatory Drugs
    • Growing Focus on Targeted Therapies and Precision Medicine Spurs Market Growth
    • Rising Awareness of Inflammation's Role in Chronic Diseases Propels Demand for Innovative Treatments
    • Integration of Anti-Inflammatory Drugs in Comprehensive Care Plans Expands Market Reach
    • Trends in Personalized Healthcare Drive Adoption of Advanced Anti-Inflammatory Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Anti-Inflammatory Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Respiratory Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Psoriasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Anti-Inflammatory Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Inflammatory Bowel Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • JAPAN
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • CHINA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • EUROPE
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • FRANCE
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • GERMANY
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • INDIA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • AFRICA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제